Paolo Cassano, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 25 | 2023 | 4644 | 3.020 |
Why?
|
| Infrared Rays | 6 | 2023 | 249 | 2.800 |
Why?
|
| Photochemotherapy | 2 | 2019 | 807 | 0.890 |
Why?
|
| Skull | 4 | 2019 | 813 | 0.880 |
Why?
|
| Brain | 10 | 2023 | 26385 | 0.650 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2018 | 187 | 0.580 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2018 | 125 | 0.560 |
Why?
|
| Phototherapy | 1 | 2019 | 377 | 0.550 |
Why?
|
| Lithium | 1 | 2019 | 601 | 0.550 |
Why?
|
| Antimanic Agents | 1 | 2019 | 522 | 0.530 |
Why?
|
| Antidepressive Agents, Second-Generation | 5 | 2006 | 503 | 0.510 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2024 | 1444 | 0.500 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 894 | 0.460 |
Why?
|
| Cerebrovascular Circulation | 2 | 2021 | 2731 | 0.460 |
Why?
|
| Anxiety Disorders | 4 | 2019 | 2690 | 0.450 |
Why?
|
| Dopamine Agonists | 3 | 2005 | 355 | 0.450 |
Why?
|
| Antidepressive Agents | 8 | 2023 | 2838 | 0.400 |
Why?
|
| Down Syndrome | 1 | 2019 | 880 | 0.390 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1061 | 0.380 |
Why?
|
| Double-Blind Method | 7 | 2022 | 12026 | 0.370 |
Why?
|
| Psychotic Disorders | 3 | 2015 | 3046 | 0.370 |
Why?
|
| Fluoxetine | 2 | 2005 | 749 | 0.370 |
Why?
|
| Hallucinations | 1 | 2013 | 360 | 0.370 |
Why?
|
| Brain Diseases | 1 | 2019 | 1563 | 0.360 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2009 | 32 | 0.350 |
Why?
|
| Body Weight | 1 | 2019 | 4669 | 0.320 |
Why?
|
| Electroencephalography | 2 | 2021 | 6150 | 0.320 |
Why?
|
| Drug Resistance | 2 | 2005 | 1609 | 0.320 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 1432 | 0.320 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 284 | 0.310 |
Why?
|
| Sampling Studies | 2 | 2019 | 623 | 0.310 |
Why?
|
| Cytokines | 2 | 2024 | 7322 | 0.280 |
Why?
|
| Depression | 8 | 2023 | 7766 | 0.280 |
Why?
|
| Treatment Outcome | 16 | 2023 | 63114 | 0.240 |
Why?
|
| Pilot Projects | 4 | 2021 | 8324 | 0.240 |
Why?
|
| Anxiety | 1 | 2018 | 4297 | 0.230 |
Why?
|
| Depressive Disorder | 5 | 2018 | 3748 | 0.230 |
Why?
|
| Alzheimer Disease | 2 | 2021 | 8037 | 0.220 |
Why?
|
| Cognition | 2 | 2019 | 6770 | 0.220 |
Why?
|
| Humans | 52 | 2024 | 744343 | 0.220 |
Why?
|
| Euphoria | 1 | 2022 | 67 | 0.210 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 5027 | 0.210 |
Why?
|
| Adult | 32 | 2023 | 214055 | 0.210 |
Why?
|
| Inflammation | 2 | 2024 | 10638 | 0.200 |
Why?
|
| Female | 36 | 2023 | 380194 | 0.200 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2019 | 876 | 0.190 |
Why?
|
| Male | 34 | 2023 | 350118 | 0.190 |
Why?
|
| Ketamine | 2 | 2017 | 500 | 0.190 |
Why?
|
| Mental Disorders | 1 | 2020 | 6600 | 0.180 |
Why?
|
| Yoga | 1 | 2023 | 253 | 0.180 |
Why?
|
| Lasers, Semiconductor | 1 | 2019 | 46 | 0.170 |
Why?
|
| Thiazoles | 2 | 2004 | 1483 | 0.170 |
Why?
|
| Hypertension | 1 | 2019 | 8480 | 0.170 |
Why?
|
| Spectrum Analysis | 1 | 2021 | 454 | 0.160 |
Why?
|
| Young Adult | 8 | 2022 | 56430 | 0.160 |
Why?
|
| Middle Aged | 24 | 2022 | 213383 | 0.150 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 169 | 0.150 |
Why?
|
| Ubiquinone | 1 | 2018 | 188 | 0.150 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 15540 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 39050 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1590 | 0.150 |
Why?
|
| Maze Learning | 1 | 2018 | 478 | 0.140 |
Why?
|
| Indoles | 1 | 2005 | 1839 | 0.140 |
Why?
|
| Nose | 1 | 2020 | 509 | 0.140 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 634 | 0.130 |
Why?
|
| Prefrontal Cortex | 3 | 2022 | 2147 | 0.130 |
Why?
|
| Hospitals, General | 1 | 2019 | 749 | 0.130 |
Why?
|
| Cultural Competency | 1 | 2018 | 289 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 1998 | 651 | 0.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2012 | 1953 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3086 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2019 | 3508 | 0.120 |
Why?
|
| Psychotherapy | 1 | 2023 | 1643 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 2886 | 0.120 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2005 | 245 | 0.110 |
Why?
|
| Universities | 1 | 2018 | 956 | 0.110 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2022 | 1432 | 0.110 |
Why?
|
| Body Constitution | 1 | 1992 | 278 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4420 | 0.110 |
Why?
|
| Reference Values | 1 | 2019 | 4982 | 0.100 |
Why?
|
| Telomere | 1 | 2018 | 910 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2019 | 2740 | 0.100 |
Why?
|
| Adolescent | 10 | 2019 | 85781 | 0.100 |
Why?
|
| Cyclohexanols | 3 | 2006 | 127 | 0.090 |
Why?
|
| Acculturation | 1 | 2012 | 182 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2951 | 0.090 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3057 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2021 | 6993 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2019 | 40561 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 15519 | 0.090 |
Why?
|
| Aged | 14 | 2020 | 163280 | 0.090 |
Why?
|
| Sex Factors | 2 | 2019 | 10397 | 0.090 |
Why?
|
| Testosterone | 1 | 2020 | 2420 | 0.090 |
Why?
|
| Public Health | 1 | 2002 | 2603 | 0.090 |
Why?
|
| Hippocampus | 2 | 2018 | 3675 | 0.090 |
Why?
|
| Citalopram | 3 | 2006 | 403 | 0.080 |
Why?
|
| Students | 1 | 2018 | 1654 | 0.080 |
Why?
|
| Language | 1 | 2018 | 1471 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2018 | 2585 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6489 | 0.080 |
Why?
|
| Rural Population | 1 | 1998 | 2210 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17446 | 0.080 |
Why?
|
| Suicidal Ideation | 1 | 2016 | 1248 | 0.070 |
Why?
|
| Cognition Disorders | 3 | 2007 | 4043 | 0.070 |
Why?
|
| Age Factors | 2 | 2019 | 18370 | 0.070 |
Why?
|
| Emotions | 1 | 2018 | 2661 | 0.070 |
Why?
|
| Boston | 1 | 2019 | 9313 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 4933 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2002 | 4558 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2015 | 21746 | 0.070 |
Why?
|
| Vasomotor System | 1 | 2006 | 209 | 0.070 |
Why?
|
| Benzothiazoles | 2 | 2004 | 248 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2019 | 6386 | 0.070 |
Why?
|
| Mitochondria | 1 | 2018 | 3520 | 0.060 |
Why?
|
| Comorbidity | 6 | 2007 | 10388 | 0.060 |
Why?
|
| Motor Skills Disorders | 1 | 2005 | 90 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 6038 | 0.060 |
Why?
|
| Anger | 1 | 2007 | 402 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4328 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2019 | 3749 | 0.060 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2005 | 434 | 0.060 |
Why?
|
| Memory Disorders | 2 | 2018 | 1184 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2019 | 53288 | 0.060 |
Why?
|
| Premenstrual Syndrome | 1 | 2004 | 109 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2013 | 2052 | 0.060 |
Why?
|
| Valine | 1 | 2005 | 413 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 4266 | 0.060 |
Why?
|
| Moclobemide | 1 | 2003 | 4 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2018 | 4245 | 0.060 |
Why?
|
| Schizophrenia | 3 | 2007 | 6882 | 0.050 |
Why?
|
| Methionine | 1 | 2005 | 590 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2009 | 3588 | 0.050 |
Why?
|
| Paroxetine | 1 | 2003 | 182 | 0.050 |
Why?
|
| Time | 1 | 2004 | 542 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 20822 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 40075 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 9959 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 1993 | 3279 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2274 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2005 | 604 | 0.050 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2004 | 360 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 10943 | 0.050 |
Why?
|
| Aging | 2 | 2018 | 8664 | 0.050 |
Why?
|
| Lung | 1 | 1998 | 9856 | 0.040 |
Why?
|
| Nurses | 1 | 2009 | 2461 | 0.040 |
Why?
|
| Postmenopause | 2 | 2006 | 2461 | 0.040 |
Why?
|
| Genotype | 3 | 2009 | 12951 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2009 | 9849 | 0.040 |
Why?
|
| Losartan | 1 | 2021 | 299 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2006 | 4258 | 0.040 |
Why?
|
| Gyrus Cinguli | 2 | 2020 | 1091 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 29063 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 12959 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 23338 | 0.040 |
Why?
|
| Pregnancy | 1 | 2019 | 29144 | 0.040 |
Why?
|
| Neuroimmunomodulation | 1 | 2018 | 157 | 0.040 |
Why?
|
| Rural Health | 1 | 1998 | 305 | 0.040 |
Why?
|
| Fatigue | 1 | 2004 | 1531 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 813 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2004 | 6459 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 924 | 0.030 |
Why?
|
| Prevalence | 1 | 2012 | 15226 | 0.030 |
Why?
|
| Animals | 4 | 2019 | 168757 | 0.030 |
Why?
|
| Sertraline | 2 | 2006 | 206 | 0.030 |
Why?
|
| Alcoholism | 1 | 2005 | 1906 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 1998 | 1616 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 35421 | 0.030 |
Why?
|
| Risk Factors | 4 | 2009 | 72290 | 0.030 |
Why?
|
| Bupropion | 2 | 2006 | 303 | 0.030 |
Why?
|
| United States | 3 | 2018 | 69872 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 2418 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7149 | 0.030 |
Why?
|
| Rabbits | 1 | 2019 | 4894 | 0.030 |
Why?
|
| Quality of Life | 2 | 2021 | 12804 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 2171 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2006 | 1030 | 0.030 |
Why?
|
| China | 1 | 1998 | 2248 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1792 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2020 | 1826 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 2538 | 0.030 |
Why?
|
| Hip | 1 | 1992 | 257 | 0.020 |
Why?
|
| Child | 1 | 2019 | 77709 | 0.020 |
Why?
|
| Obesity | 2 | 1993 | 12745 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 77449 | 0.020 |
Why?
|
| Antioxidants | 1 | 2018 | 1663 | 0.020 |
Why?
|
| Sleep | 1 | 2006 | 4623 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 2386 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2018 | 1881 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2043 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2002 | 2788 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1992 | 11725 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 8301 | 0.020 |
Why?
|
| Linear Models | 1 | 1998 | 5952 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 81183 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 9146 | 0.020 |
Why?
|
| Psychometrics | 1 | 2016 | 3002 | 0.020 |
Why?
|
| Norethindrone | 1 | 2006 | 59 | 0.020 |
Why?
|
| Abdomen | 1 | 1992 | 1118 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2006 | 116 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2006 | 295 | 0.020 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2005 | 14 | 0.020 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2005 | 37 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1993 | 1809 | 0.020 |
Why?
|
| Perimenopause | 1 | 2006 | 139 | 0.020 |
Why?
|
| Body Mass Index | 2 | 1993 | 12720 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1993 | 2017 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2005 | 158 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2005 | 144 | 0.020 |
Why?
|
| Buspirone | 1 | 2005 | 82 | 0.020 |
Why?
|
| Retreatment | 1 | 2006 | 610 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 2007 | 544 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14722 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2004 | 147 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5751 | 0.010 |
Why?
|
| Body Composition | 1 | 1993 | 2401 | 0.010 |
Why?
|
| Hot Flashes | 1 | 2006 | 317 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 977 | 0.010 |
Why?
|
| Rats | 1 | 2019 | 24260 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2005 | 647 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2005 | 909 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 8642 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 9727 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6365 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 252 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
| Diet | 1 | 1998 | 7939 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 1504 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 35136 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2007 | 1670 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 18029 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2971 | 0.010 |
Why?
|
| Estrogens | 1 | 2006 | 1566 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2005 | 2421 | 0.010 |
Why?
|
| Insulin | 1 | 1993 | 6580 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1992 | 6256 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1992 | 12354 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2005 | 1678 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4751 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25043 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 2002 | 477 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 2005 | 1221 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4186 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2003 | 57776 | 0.010 |
Why?
|
| Suicide | 1 | 2006 | 1477 | 0.010 |
Why?
|
| Incidence | 1 | 1992 | 20947 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 2708 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 6933 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 9687 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13408 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 4462 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1993 | 695 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13033 | 0.010 |
Why?
|
| Anthropometry | 1 | 1993 | 1350 | 0.010 |
Why?
|
| Fasting | 1 | 1993 | 1593 | 0.000 |
Why?
|
| Smoking | 1 | 1993 | 8987 | 0.000 |
Why?
|